Clinical Trial Update: Study of a Novel Indibulin Dosing Schedule for the Treatment of Metastatic Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update on a novel dosing schedule for indibulin in metastatic breast cancer, spanning Phase 1 and Phase 2, sponsored by Alaunos Therapeutics.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Indibulin (indibulin)

Snippet

Sponsor: Alaunos Therapeutics | Conditions: Metastatic Breast Cancer | Phase 1, Phase 2 | Status: UNKNOWN